

Industry Therapeutic Update
From Sanofi Medical

*Non-Relapsing
SPMS:*

Perspectives
From a Person
Living with MS
and a Review
of the Underlying
CNS Biology

Monday April 15th, 6:00 PM MST
Embassy Suites, Crystal Ballroom

Doors open at 5:30 PM MST,
Dinner will be served

sanofi

Agenda

Jennifer Graves

MD, PhD, MAS (Co-Chair)

Perspectives From a Person
Living with MS: A Dialogue

6:00–6:40 PM MST

Anthony Traboulsee

MD (Co-Chair)

Evidence From Within the
CNS Microenvironment: The
Need for Targeted Treatment

6:40–7:00 PM MST

Live Q&A

7:00–7:20 PM MST

Despite current treatment options, disability accumulation remains a reality for many people living with MS.



In this ITU from Sanofi Medical, we will hear from a person living with MS through a candid conversation with a physician about their MS journey. In addition, an MS expert will discuss the underlying biology of SPMS and how changes in the CNS immune microenvironment are thought to drive non-relapsing biology. BTK within disease-associated microglia will be presented as a potential target for future therapies to slow disability accumulation across the spectrum of MS.

Join us at the 2024 AAN Annual Meeting for an exciting session.



Jennifer Graves
MD, PhD, MAS (Co-Chair)

*Department of Neurosciences,
University of California, San Diego,
San Diego, CA*

Dr. Graves is a Professor of Neurosciences and Director of the Neuroimmunology Research Program at the University of California, San Diego (UCSD).

Dr. Graves received her MD and PhD in Biophysics at UT Southwestern. She trained in Neurology at UPenn, receiving the Arthur K Asbury Award for Clinical Excellence. She completed two fellowships in Neuro-ophthalmology at UPenn and in MS and Clinical Research Methods at UCSF.

Dr. Graves' current research focuses on the role of biological age on MS phenotype and has demonstrated leukocyte telomere length is associated with disability accumulation in people living with MS and a biomarker of ovarian aging is associated with MS disability in women. She develops next-generation digital tools to assess neurological patients, leveraging sensors developed in the computer control industry as well as novel applications in mobile technology.

Dr. Graves is a collaborator in several national and international research efforts in MS and participates in multi-center clinical trials. She serves on the board of IMSVisual and the editorial boards of multiple journals, including Annals of Clinical and Translational Neurology, Frontiers in Neurology, MS Journal, and Neurology.



**Anthony Trabousee
MD (Co-Chair)**

*Division of Neurology,
Department of Medicine,
The University of British Columbia,
Vancouver, Canada*

Dr. Anthony (Tony) Trabousee is the MS Canada Research Chair at the University of British Columbia (UBC) and director of the UBC MS/MRI Research Group.

Dr. Trabousee completed a residency in Neurology and fellowship in Multiple Sclerosis at the University of British Columbia Hospital in Vancouver and University College London (Queen Square). He was the lead author on the CMSC international MRI guidelines for diagnosis and treatment of MS and co-author on the International Panel Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder and the International Panel Diagnostic Criteria for Multiple Sclerosis.

Dr. Trabousee has been a principal investigator, steering committee member, or data safety monitoring board member for over 50 phase 1, 2 and 3 clinical trials including phase 2 and 3 tolebrutinib trials. His research focus is on clinical trial design, the development of practice guidelines for the use of MRI in the management of MS, and establishing advanced MRI imaging outcomes in Multiple Sclerosis, with a specific focus on developing biomarkers for future remyelination clinical trials.

Scan the QR code to participate
in polling questions and share your
feedback on the Industry Therapeutic
Update from Sanofi Medical.

Your feedback is valuable.



All responses are anonymous.

sanofi

This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

MAT-GLB-2400049 v3.0 02/2024